JP2022141670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022141670A5 JP2022141670A5 JP2022103103A JP2022103103A JP2022141670A5 JP 2022141670 A5 JP2022141670 A5 JP 2022141670A5 JP 2022103103 A JP2022103103 A JP 2022103103A JP 2022103103 A JP2022103103 A JP 2022103103A JP 2022141670 A5 JP2022141670 A5 JP 2022141670A5
- Authority
- JP
- Japan
- Prior art keywords
- aav vector
- cell
- pharmaceutical composition
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024112812A JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1519086.1A GB201519086D0 (en) | 2015-10-28 | 2015-10-28 | Gene Therapy |
| GB1519086.1 | 2015-10-28 | ||
| PCT/GB2016/053343 WO2017072515A1 (en) | 2015-10-28 | 2016-10-27 | Gene therapy |
| JP2018541571A JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541571A Division JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024112812A Division JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022141670A JP2022141670A (ja) | 2022-09-29 |
| JP2022141670A5 true JP2022141670A5 (https=) | 2022-10-07 |
Family
ID=55130363
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541571A Active JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
| JP2022103103A Pending JP2022141670A (ja) | 2015-10-28 | 2022-06-28 | 遺伝子治療 |
| JP2024112812A Pending JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541571A Active JP7126944B2 (ja) | 2015-10-28 | 2016-10-27 | 遺伝子治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024112812A Pending JP2024156706A (ja) | 2015-10-28 | 2024-07-12 | 遺伝子治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190255193A1 (https=) |
| EP (3) | EP3360890B1 (https=) |
| JP (3) | JP7126944B2 (https=) |
| KR (1) | KR102922606B1 (https=) |
| CN (4) | CN116271104A (https=) |
| AU (3) | AU2016344523B2 (https=) |
| CA (1) | CA3002125A1 (https=) |
| DK (2) | DK3360890T3 (https=) |
| ES (2) | ES2666204T5 (https=) |
| GB (1) | GB201519086D0 (https=) |
| HK (1) | HK1248723B (https=) |
| IL (3) | IL304084B2 (https=) |
| MX (1) | MX366343B (https=) |
| NO (1) | NO3262066T3 (https=) |
| PL (2) | PL3262066T5 (https=) |
| RU (1) | RU2740038C2 (https=) |
| SG (1) | SG11201802934WA (https=) |
| WO (1) | WO2017072515A1 (https=) |
| ZA (1) | ZA201802462B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108291216B (zh) | 2015-09-24 | 2022-09-16 | 宾夕法尼亚州大学信托人 | 用于治疗补体介导的疾病的组合物和方法 |
| GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| SG11202000840YA (en) * | 2017-07-31 | 2020-02-27 | Reflection Biotechnologies Ltd | Cellular models of and therapies for ocular diseases |
| EP3697920A4 (en) * | 2017-10-20 | 2022-03-02 | Gemini Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| WO2020077091A1 (en) * | 2018-10-10 | 2020-04-16 | Wisconsin Alumni Research Foundation | Kir 7.1 gene therapy vectors and methods of using the same |
| CA3117551A1 (en) * | 2018-10-23 | 2020-04-30 | Gemini Therapeutics Inc. | Compositions and methods for treating age-related macular degeneration and other diseases |
| GB201821082D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Combination of complement factors i and h, and vector encoding thereof |
| GB201821089D0 (en) * | 2018-12-21 | 2019-02-06 | Gyroscope Therapeutics Ltd | Codon-optimised complement factor I |
| WO2020206098A1 (en) * | 2019-04-03 | 2020-10-08 | Regenxbio Inc. | Gene therapy for eye pathologies |
| US20220313722A1 (en) * | 2019-09-09 | 2022-10-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb |
| CA3182800A1 (en) | 2020-06-14 | 2021-12-23 | Vertex Pharmaceuticals Inc. | Complement factor i-related compositions and methods |
| GB202009741D0 (en) | 2020-06-25 | 2020-08-12 | Freeline Therapeutics Ltd | Polynucleotide |
| US20220106611A1 (en) * | 2020-09-09 | 2022-04-07 | Homology Medicines, Inc. | Vectorized antibodies and uses thereof |
| CN117083065A (zh) | 2020-10-30 | 2023-11-17 | 庆应义塾 | 肌肉减少症相关疾病等的新颖治疗和预防 |
| GB202018320D0 (en) * | 2020-11-20 | 2021-01-06 | Univ Newcastle | Methods of producing recombinant complement proteins |
| WO2023079301A1 (en) | 2021-11-04 | 2023-05-11 | Freeline Therapeutics Limited | Assays using mutant complement factor i variants with decreased activity |
| JPWO2023145735A1 (https=) | 2022-01-25 | 2023-08-03 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| NZ544263A (en) * | 2003-06-10 | 2009-04-30 | Nsgene As | Improved secretion of neublastin |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| JP5219819B2 (ja) * | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| US7759304B2 (en) * | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| JP5332064B2 (ja) * | 2007-03-01 | 2013-11-06 | ウェルスタット イムノセラピューティクス， エルエルシー | 炎症により特徴付けられる疾患の治療 |
| CN101657097A (zh) * | 2007-03-01 | 2010-02-24 | 先进视觉疗法公司 | 以炎症为特征的疾病的治疗 |
| ES2714007T3 (es) | 2007-04-09 | 2019-05-24 | Univ Florida | Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso |
| GB0816702D0 (en) * | 2008-09-12 | 2008-10-22 | Trinity College Dublin | Complement proteins |
| GB0904427D0 (en) * | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| HK1218300A1 (zh) * | 2013-01-23 | 2017-02-10 | Musc Foundation For Research Development | 基於天然抗體的靶向結構體及其應用 |
| US20140234275A1 (en) * | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
| CA2909706C (en) * | 2013-04-17 | 2023-02-14 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
| WO2014207190A1 (en) * | 2013-06-28 | 2014-12-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for expressing a polynucleotide of interest in the retina of a subject |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| GB201519086D0 (en) * | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
-
2015
- 2015-10-28 GB GBGB1519086.1A patent/GB201519086D0/en not_active Ceased
-
2016
- 2016-10-27 PL PL16788764.5T patent/PL3262066T5/pl unknown
- 2016-10-27 NO NO16788764A patent/NO3262066T3/no unknown
- 2016-10-27 ES ES16788764T patent/ES2666204T5/es active Active
- 2016-10-27 KR KR1020187015024A patent/KR102922606B1/ko active Active
- 2016-10-27 HK HK18108313.3A patent/HK1248723B/en active IP Right Maintenance
- 2016-10-27 AU AU2016344523A patent/AU2016344523B2/en active Active
- 2016-10-27 CA CA3002125A patent/CA3002125A1/en active Pending
- 2016-10-27 WO PCT/GB2016/053343 patent/WO2017072515A1/en not_active Ceased
- 2016-10-27 CN CN202310134734.8A patent/CN116271104A/zh active Pending
- 2016-10-27 ES ES17210269T patent/ES2828050T3/es active Active
- 2016-10-27 JP JP2018541571A patent/JP7126944B2/ja active Active
- 2016-10-27 CN CN202310132380.3A patent/CN116370655A/zh active Pending
- 2016-10-27 CN CN201680073421.4A patent/CN108431030B/zh active Active
- 2016-10-27 IL IL304084A patent/IL304084B2/en unknown
- 2016-10-27 DK DK17210269.1T patent/DK3360890T3/da active
- 2016-10-27 DK DK16788764.5T patent/DK3262066T4/da active
- 2016-10-27 US US15/771,849 patent/US20190255193A1/en not_active Abandoned
- 2016-10-27 PL PL17210269T patent/PL3360890T3/pl unknown
- 2016-10-27 EP EP17210269.1A patent/EP3360890B1/en active Active
- 2016-10-27 CN CN202311083674.8A patent/CN117343960A/zh active Pending
- 2016-10-27 EP EP20187535.8A patent/EP3786176A1/en active Pending
- 2016-10-27 RU RU2018118954A patent/RU2740038C2/ru active
- 2016-10-27 SG SG11201802934WA patent/SG11201802934WA/en unknown
- 2016-10-27 EP EP16788764.5A patent/EP3262066B2/en active Active
- 2016-10-27 IL IL284577A patent/IL284577B2/en unknown
- 2016-10-27 MX MX2018005145A patent/MX366343B/es active IP Right Grant
-
2018
- 2018-04-13 ZA ZA2018/02462A patent/ZA201802462B/en unknown
- 2018-04-18 IL IL258806A patent/IL258806B/en unknown
-
2022
- 2022-05-30 AU AU2022203675A patent/AU2022203675B2/en active Active
- 2022-06-28 JP JP2022103103A patent/JP2022141670A/ja active Pending
- 2022-12-16 US US18/067,283 patent/US20230277689A1/en not_active Abandoned
-
2024
- 2024-07-12 JP JP2024112812A patent/JP2024156706A/ja active Pending
-
2025
- 2025-02-13 AU AU2025200979A patent/AU2025200979A1/en active Pending
- 2025-03-27 US US19/093,102 patent/US20250319210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022141670A5 (https=) | ||
| JP2021503914A5 (https=) | ||
| JP2018510620A5 (https=) | ||
| JP2018508519A5 (https=) | ||
| TW201629225A (zh) | 第九因子基因療法 | |
| RU2018118954A (ru) | Генная терапия | |
| US11744851B2 (en) | Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid | |
| US12467066B2 (en) | Compositions and methods for treating retinal disorders | |
| JP2021500922A5 (https=) | ||
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| RU2019103488A (ru) | Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12 | |
| JP2023545229A5 (https=) | ||
| EP4703475A1 (en) | Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus | |
| IL312657A (en) | Codon-optimised complement factor i | |
| JP7627961B2 (ja) | バルデー・ビードル症候群の遺伝子治療 | |
| JP2022523050A5 (https=) | ||
| JP2023536067A5 (https=) | ||
| RU2021120124A (ru) | Кодон-оптимизированный фактор комплемента i | |
| CN115997012B (zh) | Rpe65相关眼睛疾病和障碍的治疗 | |
| RU2021119359A (ru) | Фактор комплемента i и кофактор фактора комплемента i, кодирующие их векторы и применение в терапевтических целях | |
| RU2023135479A (ru) | Кодон-оптимизированный фактор комплемента i | |
| Fehrman et al. | The co-transduction conundrum: Improving dual rAAV delivery through co-administration of capsid serotypes with complementary tropism | |
| TW202434733A (zh) | 重組腺相關病毒載體 | |
| Karimipoor | Recent Advances in Hemophilia Gene Therapy (STUDY BREAK) | |
| EA046019B1 (ru) | Композиции и способы лечения нарушений сетчатки |